Constellation Stock Analysis

CNST -  USA Stock  

USD 33.76  0.06  0.18%

The newest price gain of Constellation Pharmaceuticals could raise concerns from private investors as the firm it trading at a share price of 33.76 on 1,979,300 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 8.73. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Constellation Pharmaceuticals partners.
Continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Constellation Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Constellation Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Constellation stock analysis module also helps to analyze the Constellation Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Constellation Stock Analysis Notes

About 109.0% of the company shares are held by institutions such as insurance companies. The book value of Constellation Pharmaceuticals was currently reported as 8.6. The company recorded a loss per share of 2.82. Constellation Pharmaceuticals had not issued any dividends in recent years. Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Constellation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 154 people. For more info on Constellation Pharmaceuticals please contact Keith Dionne at 617 714 0555 or go to http://www.constellationpharma.com.

Constellation Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Constellation Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Constellation Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Constellation Pharmaceuticals is way too risky over 90 days horizon
Constellation Pharmaceuticals appears to be risky and price may revert if volatility continues
Constellation Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (140.98 M) with loss before overhead, payroll, taxes, and interest of (28.37 M).
Constellation Pharmaceuticals currently holds about 382.08 M in cash with (125.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.97.
Constellation Pharmaceuticals has a very weak financial position based on the latest SEC disclosures
Latest headline from www.marketscreener.com: MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals - Marketscreener.com

Constellation Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Constellation Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Constellation Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Constellation Largest EPS Surprises

Earnings surprises can significantly impact Constellation Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-08-05
2020-06-30-0.6348-0.6993-0.064510 
2018-11-08
2018-09-30-0.6821-0.81-0.127918 
View All Earnings Estimates

Constellation Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Constellation Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Constellation Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Constellation Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of June 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders. Unclassified Corporate Event. Entry into a Material Definitive Agreement
View
16th of February 2021
Unclassified Corporate Event
View
12th of February 2021
Unclassified Corporate Event
View
4th of February 2021
Unclassified Corporate Event
View
2nd of February 2021
Unclassified Corporate Event
View
1st of February 2021
Unclassified Corporate Event
View
7th of December 2020
Other Events
View
18th of November 2020
Entry into a Material Definitive Agreement
View

Constellation Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Constellation Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Constellation Pharmaceuticals backward and forwards among themselves. Constellation Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Constellation Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares4.4 M103 M
Vr Adviser LlcCommon SharesM94 M
Avoro Capital Advisors LlcCommon SharesM69 M
Blackrock IncCommon Shares2.6 M62 M
Column Group LlcCommon Shares2.6 M61.4 M
Ra Capital Management LpCommon Shares2.2 M52.4 M
State Street CorpCommon Shares2.2 M51.3 M
Note, although Constellation Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Constellation Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Constellation Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Constellation Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Constellation Profitablity

Constellation Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Constellation Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Constellation Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Constellation Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Constellation Pharmaceuticals' profitability requires more research than a typical breakdown of Constellation Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.27) (0.30) 
Return on Average Equity(0.31) (0.31) 
Return on Invested Capital(0.41) (0.42) 

Management Efficiency

The entity has return on total asset (ROA) of (22.41) % which means that it has lost $22.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (40.7) %, meaning that it created substantial loss on money invested by shareholders. Constellation Pharmaceuticals management efficiency ratios could be used to measure how well constellation pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.3 in 2021. Return on Average Equity is likely to drop to -0.31 in 2021. Constellation Pharmaceuticals Total Liabilities is comparatively stable at the moment as compared to the past year. Constellation Pharmaceuticals reported Total Liabilities of 31.13 Million in 2020. Liabilities Non Current is likely to gain to about 597.3 K in 2021, whereas Current Liabilities is likely to drop slightly above 26.6 M in 2021.
Last ReportedProjected for 2021
Book Value per Share 9.15  9.87 
Enterprise Value over EBIT(10.00) (10.79) 
Enterprise Value over EBITDA(10.52) (11.35) 
Price to Book Value 3.34  3.49 
Tangible Assets Book Value per Share 9.84  13.22 
Enterprise Value1.3 B1.2 B
Tangible Asset Value441.9 M350.4 M

Technical Drivers

As of the 19th of June, Constellation Pharmaceuticals shows the Mean Deviation of 3.22, risk adjusted performance of 0.0459, and Downside Deviation of 3.29. Constellation Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Constellation Pharmaceuticals, which can be compared to its rivals. Please confirm Constellation Pharmaceuticals coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Constellation Pharmaceuticals is priced correctly, providing market reflects its regular price of 33.76 per share. Given that Constellation Pharmaceuticals has jensen alpha of 0.4774, we suggest you to validate Constellation Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Constellation Pharmaceuticals Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Constellation Pharmaceuticals double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Constellation Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Constellation Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Constellation Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Constellation Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
James Audia over two weeks ago via Macroaxis 
Acquisition by James Audia of 13171 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Mark Goldsmith over three months ago via Macroaxis 
Exercise or conversion by Mark Goldsmith of 14987 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Emma Reeve over three months ago via Macroaxis 
Exercise or conversion by Emma Reeve of 1100 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Humphrey Jeffrey over three months ago via Macroaxis 
Acquisition by Humphrey Jeffrey of 35055 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Mark Goldsmith over three months ago via Macroaxis 
Bona fide gift to Mark Goldsmith of 2000 shares of Constellation Pharmaceuticals subject to Section 16
Valentine Karen over three months ago via Macroaxis 
Exercise or conversion by Valentine Karen of 17203 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Mark Goldsmith over three months ago via Macroaxis 
Sale by Mark Goldsmith of 4020 shares of Constellation Pharmaceuticals
Emma Reeve over three months ago via Macroaxis 
Exercise or conversion by Emma Reeve of 4542 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Column Group L P over six months ago via Macroaxis 
Exercise of in-the-money or at-the-money derivative position by Column Group L P of 30107 shares of Constellation Pharmaceuticals
Humphrey Jeffrey over six months ago via Macroaxis 
Acquisition by Humphrey Jeffrey of 133000 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Emma Reeve over a year ago via Macroaxis 
Exercise or conversion by Emma Reeve of 589 shares of Constellation Pharmaceuticals subject to Rule 16b-3
Mark Goldsmith over a year ago via Macroaxis 
Exercise or conversion by Mark Goldsmith of 300 shares of Constellation Pharmaceuticals subject to Rule 16b-3

Constellation Pharmaceuticals Predictive Daily Indicators

Constellation Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Constellation Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Constellation Pharmaceuticals Forecast Models

Constellation Pharmaceuticals time-series forecasting models is one of many Constellation Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Constellation Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Constellation Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Constellation Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Constellation shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Constellation Pharmaceuticals. By using and applying Constellation Stock analysis, traders can create a robust methodology for identifying Constellation entry and exit points for their positions.
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The companys lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 12 clinical trial to treat solid tumors and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Current Constellation Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Constellation analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Constellation analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
44.25Hold8Odds
Constellation Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Constellation analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Constellation stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Constellation Pharmaceuticals, talking to its executives and customers, or listening to Constellation conference calls.
Constellation Analyst Advice Details

Constellation Stock Analysis Indicators

Constellation Pharmaceuticals stock analysis indicators help investors evaluate how Constellation Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Constellation Pharmaceuticals shares will generate the highest return on investment. By understating and applying Constellation Pharmaceuticals stock analysis, traders can identify Constellation Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio15.08
Fifty Two Week Low17.00
Shares Short Prior Month6.47M
Average Daily Volume Last 10 Day2.03M
Average Daily Volume In Three Month1.31M
Shares Percent Shares Out15.97%
Short Percent Of Float21.29%
Forward Price Earnings-8.77
Float Shares32.57M
Fifty Two Week High39.30
Enterprise Value To Ebitda-3.99
Fifty Day Average24.68
Two Hundred Day Average27.76
Continue to Trending Equities. Note that the Constellation Pharmaceuticals information on this page should be used as a complementary analysis to other Constellation Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Constellation Pharmaceuticals Stock analysis

When running Constellation Pharmaceuticals price analysis, check to measure Constellation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Constellation Pharmaceuticals is operating at the current time. Most of Constellation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Constellation Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Constellation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Constellation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
The market value of Constellation Pharmaceuticals is measured differently than its book value, which is the value of Constellation that is recorded on the company's balance sheet. Investors also form their own opinion of Constellation Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Constellation Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Constellation Pharmaceuticals' market value can be influenced by many factors that don't directly affect Constellation Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Constellation Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Constellation Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Constellation Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.